3 Promising Penny Stocks With Market Caps Up To $500M

Over the last 7 days, the market has remained flat, while over the past 12 months, it has risen by 14%, with earnings expected to grow by 17% per annum over the next few years. Investing in penny stocks — a somewhat outdated term but still relevant — can offer growth opportunities, particularly in smaller or newer companies that demonstrate strong financial health. In this article, we explore three promising penny stocks that combine stability with potential for upside, making them intriguing options for investors seeking to tap into lesser-known areas of the market.

Let's dive into some prime choices out of the screener.

Expensify (EXFY)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Expensify, Inc. offers a cloud-based expense management software platform serving both the United States and international markets, with a market cap of $223.41 million.

Operations: The company's revenue is primarily generated from its Internet Software & Services segment, totaling $138.10 million.

Market Cap: $223.41M

Expensify, Inc. has shown resilience despite being unprofitable, with a market cap of US$223.41 million and revenue of US$138.10 million from its cloud-based expense management platform. The company is debt-free, with short-term assets exceeding liabilities and a cash runway extending beyond three years even if free cash flow shrinks slightly. Recent integrations with platforms like Campfire and DualEntry enhance its service offerings, potentially boosting user engagement among finance teams worldwide. However, the stock remains volatile and shares have not been diluted recently, indicating cautious capital management amidst ongoing losses and earnings volatility challenges.

• Click to explore a detailed breakdown of our findings in Expensify's financial health report.
• Assess Expensify's future earnings estimates with our detailed growth reports.

Myriad Genetics (MYGN)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company that develops molecular tests, with a market cap of approximately $396.95 million.

Operations: The company's revenue is derived from its Biotechnology segment, which generated $806.6 million.

Market Cap: $396.95M

Myriad Genetics, Inc., with a market cap of US$396.95 million and revenue of US$806.6 million, remains unprofitable but shows potential through strategic alliances in precision oncology. The recent collaboration with SOPHiA GENETICS aims to advance prostate cancer diagnostics, potentially expanding Myriad's market reach. Despite its high share price volatility and increasing debt-to-equity ratio over five years, the company maintains sufficient cash runway for over three years under stable conditions. While management is relatively inexperienced with an average tenure of 1.5 years, the board brings stability with an average tenure of 6.6 years.

• Click here and access our complete financial health analysis report to understand the dynamics of Myriad Genetics.
• Evaluate Myriad Genetics' prospects by accessing our earnings growth report.

Dingdong (Cayman) (DDL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Dingdong (Cayman) Limited is an e-commerce company operating in China with a market cap of $470.83 million.

Operations: The company's revenue is primarily generated from its online retail segment, which accounts for CN¥18.55 billion.

Market Cap: $470.83M

Dingdong (Cayman) Limited, with a market cap of US$470.83 million, operates in e-commerce and has shown revenue growth to CN¥73.2 million for Q2 2026, despite being unprofitable. The company benefits from strong financial positioning with short-term assets of CN¥8.1 billion surpassing both short- and long-term liabilities. It remains debt-free and enjoys a stable cash runway exceeding three years due to positive free cash flow growth of 64.3% annually. Recent board changes include the appointment of Ms. Le Yu as an independent director, potentially enhancing governance stability with her extensive legal and strategic experience in the company’s sector.

• Click here to discover the nuances of Dingdong (Cayman) with our detailed analytical financial health report.
• Examine Dingdong (Cayman)'s earnings growth report to understand how analysts expect it to perform.

Key Takeaways

• Click this link to deep-dive into the 325 companies within our US Penny Stocks screener.
• Interested In Other Possibilities? The end of cancer? These 37 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com